{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.9","upperLimit":"-0.6","value":"-3.51"},{"groupId":"OG001","lowerLimit":"-15.1","upperLimit":"-1.6","value":"-4.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"From baseline to Cycle 3 day 1 of main study therapy"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.9","upperLimit":"-0.4","value":"-0.85"},{"comment":"Only 1 participant analyzed","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"-17.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"From baseline to time of progression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Expression levels of the free form of soluble CS1 were analyzed at different timepoints from serum samples derived from peripheral blood collection","dispersionType":"Full Range","groups":[{"description":"Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG000","title":"E-Ld Cohort"},{"description":"Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG001","title":"Ld Cohort"}],"paramType":"MEDIAN","populationDescription":"All treated participants with measurements available at baseline and at cycle 3 day 1 of study therapy or at baseline and at the time of progression.","reportingStatus":"POSTED","timeFrame":"From baseline (screening) to cycle 3 day 1 of the main study therapy (up to 64 days) and from baseline (screening) to time of progression (up to approximately 31 months)","title":"Change From Baseline in the Levels of CS1 Soluble Form (sCS1) in Serum During Therapy and At Progression","type":"SECONDARY","unitOfMeasure":"ug/L"}